Fuse Oncology, the structured AI platform for radiation oncology, announced the launch of FuseRx, a prescribing and treatment-intent solution for radiation oncology. FuseRx will make its public debut at the 68th AAPM Annual Meeting & Exhibition, July 19–22 in Vancouver, B.C.
FuseRx is the keystone of the Fuse platform, connecting the consult to simulation, planning, and treatment. Physicians create a complete, structured treatment intent simulation orders, prescriptions, target and organ-at-risk goals, and supporting orders in a single guided workflow. Clinic-configurable templates, a built-in validation engine with configurable safety checks and hard stops, and a full change-request audit trail replace fragmented, paper-and-PDF prescribing processes that slow the start of care.
“Fuse exists to deliver on a promise: consult to care in 24 hours. That’s what patients expect, and when you build the workflow right, it takes the pressure and busywork off your team while improving outcomes for everyone. We call that the speed of the patient. FuseRx is the keystone everything builds on the physician driving the workflow forward,” said James Bauler, Chief Executive Officer, Fuse Oncology.
Also Read: Eurofins Acquires Element’s Life Sciences Testing Unit
FuseRx is built to support clinical pathways at the point of prescribing whether institution-specific protocols or published evidence-based guidelines. Building on the strategic agreement announced in March 2025, ACRO’s ACROPath® pathways will be among the first to integrate directly into the FuseRx workflow, giving clinicians guideline-concordant decision support at the moment treatment decisions are made reducing care variation while preserving physician judgment.
“ACRO is excited to see ACROPath move from agreement to reality inside FuseRx. Putting our pathways in front of physicians at the point of prescribing is exactly how evidence-based care should be delivered,” said Christopher Jahraus, MD, FACRO, American College of Radiation Oncology.
Source: PRNewswire
